Hamstra R D, Block M H, Schocket A L
JAMA. 1980 May 2;243(17):1726-31.
Four hundred seventy-one adult patients and ten adult prisoner volunteers received 2,099 intravenous (IV) injections of iron dextran (Imferon), usually 250 to 500 mg at less than 100 mg/min. Intravenous iron supplies enough iron to permit RBC formation greater than 50 mL/day and repletion of tissue iron. Tissue iron did not always supply iron at an optimal rate. Hemoglobin production was higher after IV than oral or intramuscular iron if the hemoglobin level was less than 9 g/dL. Three life-threatening immediate anaphylactoid and eight severe delayed reactions were observed. There were no deaths. Delayed reactions were more frequent in women and collagen-vascular diseases and less frequent in pregnancy. Because anaphylactoid reactions are serious and unpredictable, IV iron dextran should be used only when iron deficiency anemia cannot be treated adequately with oral iron.
471名成年患者和10名成年囚犯志愿者接受了2099次右旋糖酐铁（Imferon）静脉注射，通常剂量为250至500毫克，注射速度低于100毫克/分钟。静脉注射铁剂可提供足够的铁，以允许红细胞生成量超过每天50毫升，并补充组织铁。组织铁并非总能以最佳速率供应铁。如果血红蛋白水平低于9克/分升，静脉注射铁剂后血红蛋白生成量高于口服或肌肉注射铁剂。观察到3例危及生命的即刻类过敏反应和8例严重的迟发反应。无死亡病例。迟发反应在女性和胶原血管疾病患者中更常见，在孕妇中较少见。由于类过敏反应严重且不可预测，仅在缺铁性贫血无法用口服铁剂充分治疗时才应使用静脉注射右旋糖酐铁。
